ARTICLE | Company News
Genentech updates Herceptin warning
September 2, 2005 1:42 AM UTC
DNA issued a "Dear Healthcare Professional" letter for Herceptin trastuzumab to include data on cardiotoxicity seen in recent trials. In the Phase III NSABP B-31 study in 2,043 patients and the NCCTG ...